However, given that inhibition of γ-secretase-mediated Notch cleavage is a primary focus for the development of targeted therapeutics in GBM (including application in clinical trials such as RO4929097)47, our data may provide a strong rationale that targeting TUG1 is a more specific and potent therapeutic approach to eliminate the GSC population. This evidence concerns the gene TUG1 and glioblastoma.